Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.

Weiss M, Panagiotopoulos C, Giles L, Gibbins C, Kuzeljevic B, Davidson J, Harrison R.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):575-82. doi: 10.1089/cap.2009.0050.

PMID:
19877982
2.
3.

A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.

Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.

J Clin Psychopharmacol. 2017 Oct;37(5):590-594. doi: 10.1097/JCP.0000000000000747.

PMID:
28806385
4.

Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality.

Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU.

J Child Adolesc Psychopharmacol. 2009 Oct;19(5):563-73. doi: 10.1089/cap.2009.0051.

5.
6.
8.

Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.

Armenteros JL, Lewis JE, Davalos M.

J Am Acad Child Adolesc Psychiatry. 2007 May;46(5):558-65.

PMID:
17450046
9.

Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation.

Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA.

J Am Acad Child Adolesc Psychiatry. 2005 Aug;44(8):748-55.

PMID:
16034276
10.

Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.

Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):203-12. doi: 10.1089/cap.2014.0104.

11.

Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.

Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR Jr, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG.

J Child Adolesc Psychopharmacol. 2015 Apr;25(3):213-24. doi: 10.1089/cap.2014.0109.

12.

The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.

G√ľnther T, Herpertz-Dahlmann B, Jolles J, Konrad K.

J Child Adolesc Psychopharmacol. 2006 Dec;16(6):725-35.

PMID:
17201616
13.

Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.

Farmer CA, Epstein JN, Findling RL, Gadow KD, Arnold LE, Kipp H, Kolko DJ, Butter E, Schneider J, Bukstein OG, McNamara NK, Molina BS, Aman MG.

J Child Adolesc Psychopharmacol. 2017 Mar;27(2):117-124. doi: 10.1089/cap.2016.0040. Epub 2016 Jun 27.

14.

Risperidone-to-methylphenidate switch reaction in children: three cases.

Sabuncuoglu O.

J Psychopharmacol. 2007 Mar;21(2):216-9. Erratum in: J Psychopharmacol. 2008 Aug;22(6):699.

PMID:
17329303
16.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
17.

Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.

Capone GT, Goyal P, Grados M, Smith B, Kammann H.

J Dev Behav Pediatr. 2008 Apr;29(2):106-16. doi: 10.1097/DBP.0b013e318165c100.

PMID:
18349709
18.

The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.

Ince E, Algedik P, Demirdogen ES, Emul M, Demir T.

J Child Adolesc Psychopharmacol. 2015 May;25(4):378-9. doi: 10.1089/cap.2014.0148. Epub 2015 Apr 28. No abstract available.

PMID:
25920038
19.

Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects.

Ahmann PA, Theye FW, Berg R, Linquist AJ, Van Erem AJ, Campbell LR.

Pediatrics. 2001 Jan;107(1):E10.

PMID:
11134474
20.

Co-occurring weight problems among children with attention deficit/hyperactivity disorder: the role of executive functioning.

Graziano PA, Bagner DM, Waxmonsky JG, Reid A, McNamara JP, Geffken GR.

Int J Obes (Lond). 2012 Apr;36(4):567-72. doi: 10.1038/ijo.2011.245. Epub 2011 Dec 13.

PMID:
22158266

Supplemental Content

Support Center